Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 42, 2010, Pages 18097-18102

  Konno, Tetsuo ^a   Chen, Dan ^a,h   Wang, Libin ^a   Wakimoto, Hiroko ^b   Teekakirikul, Polakit ^a   Nayor, Matthew ^a   Kawana, Masataka ^a   Eminaga, Seda ^a   Gorham, Joshua M ^a   Pandya, Kumar ^c   Smithies, Oliver ^c   Naya, Francisco J ^d   Olson, Eric N ^e   Seidman, J G ^a   Seidman, Christine E ^a,f,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Boston University   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h Seahorse Bioscience   (United States)

Author keywords

Fibrosis; Hypertrophy; Sarcomere protein gene mutation

Indexed keywords

HISTONE DEACETYLASE 2; MYOCYTE ENHANCER FACTOR 2; MYOSIN HEAVY CHAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HEART MUSCLE FIBROSIS; HISTOCHEMISTRY; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMERE; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHY, HYPERTROPHIC; FIBROSIS; GENES, REPORTER; MICE; MYOGENIC REGULATORY FACTORS; NECROSIS; PHOSPHORYLATION; POINT MUTATION;

MUS;

EID: 78149242336     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1012826107     Document Type: Article

References (35)

1. Ingles J, et al. (2005) Compound and double mutations in patients with hypertrophic cardiomyopathy: Implications for genetic testing and counselling. J Med Genet 42:e59.
2. Maron BJ, Spirito P (1998) Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 81:1339-1344. (Pubitemid 28268673)
3. Fatkin D, et al. (1999) Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene. J Clin Invest 103:147-153. (Pubitemid 29031173)
4. Tanaka M, et al. (1987) Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 75:1130-1139. (Pubitemid 17081019)
5. Knaapen P, et al. (2008) Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 294:H986-H993.
6. Tuunanen H, et al. (2007) Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: A positron emission tomography study. J Nucl Cardiol 14:354-365.
7. Adabag AS, et al. (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51:1369-1374.
8. Spirito P, Maron BJ, Bonow RO, Epstein SE (1987) Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 60:123-129. (Pubitemid 17137391)
9. Geisterfer-Lowrance AA, et al. (1996) A mouse model of familial hypertrophic cardiomyopathy. Science 272:731-734. (Pubitemid 26000280)
10. Georgakopoulos D, et al. (1999) The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. Nat Med 5:327-330. (Pubitemid 29124370)
11. Wolf CM, et al. (2005) Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc Natl Acad Sci USA 102:18123-18128.
12. Zhang CL, et al. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110:479-488.
13. Kim Y, et al. (2008) The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest 118:124-132.
14. Zhang T, et al. (2007) CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem 282:35078-35087.
15. Naya FJ, et al. (2002) Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med 8:1303-1309.
16. Potthoff MJ, Olson EN (2007) MEF2: A central regulator of diverse developmental programs. Development 134:4131-4140.
17. Naya FJ, Wu C, Richardson JA, Overbeek P, Olson EN (1999) Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development 126:2045-2052. (Pubitemid 29271690)
18. Yoshida T (2008) MCAT elements and the TEF-1 family of transcription factors in muscle development and disease. Arterioscler Thromb Vasc Biol 28:8-17.
19. Kim JB, et al. (2007) Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science 316:1481-1484.
20. Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN (2006) CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest 116:1853-1864. (Pubitemid 44033310)
21. Backs J, et al. (2009) The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 106:2342-2347.
22. Fielitz J, et al. (2008) Requirement of protein kinase D1 for pathological cardiac remodeling. Proc Natl Acad Sci USA 105:3059-3063.
23. Pandya K, Kim HS, Smithies O (2006) Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci USA 103:16864-16869. (Pubitemid 44737344)
24. van Oort RJ, et al. (2006) MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. Circulation 114:298-308.
25. Petersen SE, et al. (2007) Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: New insights from multiparametric magnetic resonance imaging. Circulation 115:2418-2425.
26. Tsoutsman T, Bagnall RD, Semsarian C (2008) Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure. Clin Exp Pharmacol Physiol 35:1349-1357.
27. Tyska MJ, et al. (2000) Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res 86:737-744.
28. Spindler M, et al. (1998) Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest 101:1775-1783. (Pubitemid 28198508)
29. Fatkin D, et al. (2000) An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 106:1351-1359.
30. Sparling DP, Griesel BA, Weems J, Olson AL (2008) GLUT4 enhancer factor (GEF) interacts with MEF2A and HDAC5 to regulate the GLUT4 promoter in adipocytes. J Biol Chem 283:7429-7437.
31. Murphy G, Nagase H (2008) Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: Destruction or repair? Nat Clin Pract Rheumatol 4:128-135.
32. Sanada H, et al. (1993) Increased left atrial chamber stiffness in hypertrophic cardiomyopathy. Br Heart J 69:31-35. (Pubitemid 23036638)
33. Manabe I, Shindo T, Nagai R (2002) Gene expression in fibroblasts and fibrosis: Involvement in cardiac hypertrophy. Circ Res 91:1103-1113. (Pubitemid 36076358)
34. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H (2007) Return to the fetal gene program protects the stressed heart: A strong hypothesis. Heart Fail Rev 12:331-343.
35. Sabbah HN, Sharov VG, Lesch M, Goldstein S (1995) Progression of heart failure: A role for interstitial fibrosis. Mol Cell Biochem 147:29-34.